Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281434 | 0.88 | HTR2A (0.63) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL10088110 | 0.85 | GPR84 (0.71) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL7004405 | 0.85 | HTR2A (0.73) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL9889542 | 0.83 | HTR2A (0.71) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL11603000 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL11359977 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL5598636 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL7391194 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL18328036 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2SLC6A4 | |
| SCHEMBL5402680 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-10-07 | — | — | US | disclosed |
| CN-113166182-A | Aminopeptidase A inhibitor and pharmaceutical composition comprising the same | 量子基因公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-103380130-A | Novel pyrazole and imidazole derivatives useful as orexin antagonists | ACTELION PHARMACEUTICALS LTD | 2013-10-30 | — | — | CN | disclosed |
| EP-0345808-B1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-01-11 | — | — | EP | disclosed |
| US-4954502-A | Antidepressants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0345808-A1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | Bristol-Myers Squibb Company (US) | 1989-12-13 | — | — | EP | disclosed |
| EP-0061333-B1 | 9-(2-(3-INDOLYL)ETHYL)-1-OXA-4,9-DIAZASPIRO(5.5)UNDECAN-3-ONES | SYNTEX (U.S.A.) INC. (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0061333-A1 | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones | SYNTEX (U.S.A.) INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4332804-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIA, MIGRAINE, VASOSPASTIC DISORDERS AND ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-06-01 | — | — | US | disclosed |
| US-4242347-A | Hypotensive indolylalkylpiperidyl guanidines and isoureas | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| US-4147786-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4073911-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | HTR2A 3749/4885GPR84 1339/4885KEAP1 1303/4885 |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ANPEP, DNPEP, ENPEP | HTR2A 3749/4885GPR84 1339/4885KEAP1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.